Biosafety of mesoporous silica nanoparticles

[EN] Mesoporous silica nanoparticles (MSNs) have attracted the attention of chemists, who have developed numerous systems for the encapsulation of a plethora of molecules, allowing the use of mesoporous silica nanoparticles for biomedical applications. MSNs have been extensively studied for their us...

ver descrição completa

Detalhes bibliográficos
Autores: Lérida-Viso, Araceli, Estepa-Fernández, Alejandra, García-Fernández, Alba|||0000-0002-8416-1674, Martí-Centelles, Vicente|||0000-0002-9142-9392, Martínez-Máñez, Ramón|||0000-0001-5873-9674
Formato: artículo
Fecha de publicación:2023
País:España
Recursos:Universitat Politècnica de València (UPV)
Repositorio:RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Idioma:inglés
OAI Identifier:oai:riunet.upv.es:10251/205810
Acesso em linha:https://riunet.upv.es/handle/10251/205810
Access Level:acceso abierto
Palavra-chave:Mesoporous silica nanoparticles (MSNs)
Biodistribution
Biocompatibility
Biodegradation
Clearance
Clinical application
QUIMICA INORGANICA
Descrição
Resumo:[EN] Mesoporous silica nanoparticles (MSNs) have attracted the attention of chemists, who have developed numerous systems for the encapsulation of a plethora of molecules, allowing the use of mesoporous silica nanoparticles for biomedical applications. MSNs have been extensively studied for their use in nanomedicine, in applications such as drug delivery, diagnosis, and bioimaging, demonstrating significant in vivo efficacy in different preclinical models. Nevertheless, for the transition of MSNs into clinical trials, it is imperative to understand the characteristics that make MSNs effective and safe. The biosafety properties of MSNs in vivo are greatly influenced by their physicochemical characteristics such as particle shape, size, surface modification, and silica framework. In this review, we compile the most relevant and recent progress in the literature up to the present by analyzing the contributions on biodistribution, biodegradability, and clearance of MSNs. Furthermore, the ongoing clinical trials and the potential challenges related to the administration of silica materials for advanced therapeutics are discussed. This approach aims to provide a solid overview of the state-of-the-art in this field and to encourage the translation of MSNs to the clinic.